Trevi Therapeutics, Inc. Skyrocketed
Trevi Therapeutics, Inc. (TRVI:NASDAQ) rocketted at $3.29, a gain of 92.4%. On Mon 30 Mar 20, TRVI:NASDAQ touched a New 2-Week Low of $1.71. The stock appeared on our News Catalysts scanner on Tue 17 Mar 20 at 04:08 AM in the 'INVESTOR UPDATE' category. From Mon 16 Mar 20, the stock recorded 40.00% Up Days and 54.55% Green Days
About Trevi Therapeutics, Inc. (TRVI:NASDAQ)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Top 10 Gainers:
- SG Blocks, Inc. (SGBX:NASDAQ), 351.46%
- VIVUS, Inc. (VVUS:NASDAQ), 278.87%
- Greenland Technologies Holding Corporation (GTEC:NASDAQ), 106.25%
- Barnwell Industries, Inc. (BRN:NYSEMKT), 93.02%
- Trevi Therapeutics, Inc. (TRVI:NASDAQ), 92.4%
- Rosehill Resources Inc. (ROSE:NASDAQ), 51.85%
- Sanchez Midstream Partners LP (SNMP:NYSEMKT), 43.67%
- Organovo Holdings, Inc. (ONVO:NASDAQ), 43.36%
- PBF Logistics LP (PBFX:NYSE), 43.22%
- ChinaNet Online Holdings, Inc. (CNET:NASDAQ), 37.68%